"Anyway, what matters are the Phase 3 results. As with AMRN, there will be a pre-results company and a post-results company, and the two will have very little in common."

No argument there. However, it is extremely uncommon for a CVOT this late in the game with such all stars on the clinical steering committee to be so off the radar. The company isn't doing themselves any favors by staying so quiet or being so ambiguous or habitually off the mark when they do communicate. As for "expecting".... when the company gives guidance with about 3.5 months left in the year and again with less than 2 months left in the year that they anticipate end of dosing ( 250 adjudicated events) by end of year and top-line in Q1......the proximity of those statements to the end of the year SHOULD leave very little wiggle room for error. We now sit 45 days past this end of dosing  prediction.... almost double the time projected at November's BIO Europe to hit the end of dosing mark. This close to the end there shouldn't be this much ambiguity in the company's communications. 220 events on Tuesday 2/12 when they expected 250 by end of last year? The ambiguity and confusion conveyed by Resverlogix isn't exactly instilling confidence in the company. Why they can't see this is a mystery. I "expect" more from them.

BearDownAZ